The NHS is right to drive a hard bargain for new drugs
From our UK edition
It is not often that the NHS gets accused of being too good at negotiating down costs. But that seems to be gist of the case levelled against it regarding the cost of drugs. AstraZeneca has paused the expansion of a research facility in Cambridge and US pharmaceutical firm Merck has cancelled a plan to